These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 24582759)

  • 1. Elevated melatonin levels in natalizumab-treated female patients with relapsing-remitting multiple sclerosis: relationship to oxidative stress.
    Bahamonde C; Conde C; Agüera E; Lillo R; Luque E; Gascón F; Feijóo M; Cruz AH; Sánchez-López F; Túnez I
    Eur J Pharmacol; 2014 May; 730():26-30. PubMed ID: 24582759
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Natalizumab and reduction of carbonylated proteins in patients with multiple sclerosis].
    Tasset I; Aguera E; Gascon F; Giraldo AI; Salcedo M; Cruz AH; Sanchez F; Tunez I
    Rev Neurol; 2012 Apr; 54(8):449-52. PubMed ID: 22492096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of natalizumab on oxidative damage biomarkers in relapsing-remitting multiple sclerosis.
    Tasset I; Bahamonde C; Agüera E; Conde C; Cruz AH; Pérez-Herrera A; Gascón F; Giraldo AI; Ruiz MC; Lillo R; Sánchez-López F; Túnez I
    Pharmacol Rep; 2013; 65(3):624-31. PubMed ID: 23950585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of Melatonin on Serum Pro-inflammatory Cytokines and Oxidative Stress Markers in Relapsing Remitting Multiple Sclerosis.
    Sánchez-López AL; Ortiz GG; Pacheco-Moises FP; Mireles-Ramírez MA; Bitzer-Quintero OK; Delgado-Lara DLC; Ramírez-Jirano LJ; Velázquez-Brizuela IE
    Arch Med Res; 2018 Aug; 49(6):391-398. PubMed ID: 30595364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Natalizumab for relapsing-remitting multiple sclerosis.
    Horga A; Tintoré M
    Neurologia; 2011; 26(6):357-68. PubMed ID: 21193250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Natalizumab strongly suppresses cortical pathology in relapsing-remitting multiple sclerosis.
    Rinaldi F; Calabrese M; Seppi D; Puthenparampil M; Perini P; Gallo P
    Mult Scler; 2012 Dec; 18(12):1760-7. PubMed ID: 22570359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Switching from natalizumab to fingolimod: an observational study.
    Sempere AP; Martín-Medina P; Berenguer-Ruiz L; Pérez-Carmona N; Sanchez-Perez R; Polache-Vengud J; Feliu-Rey E
    Acta Neurol Scand; 2013 Aug; 128(2):e6-e10. PubMed ID: 23336398
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of freedom from disease activity in natalizumab treated-patients with multiple sclerosis.
    Prosperini L; Giannì C; Barletta V; Mancinelli C; Fubelli F; Borriello G; Pozzilli C
    J Neurol Sci; 2012 Dec; 323(1-2):104-12. PubMed ID: 23006974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Voxel-wise magnetization transfer imaging study of effects of natalizumab and IFNβ-1a in multiple sclerosis.
    Zivadinov R; Dwyer MG; Hussein S; Carl E; Kennedy C; Andrews M; Hojnacki D; Heininen-Brown M; Willis L; Cherneva M; Bergsland N; Weinstock-Guttman B
    Mult Scler; 2012 Aug; 18(8):1125-34. PubMed ID: 22194217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Natalizumab treatment shows no clinically meaningful effects on immunization responses in patients with relapsing-remitting multiple sclerosis.
    Kaufman M; Pardo G; Rossman H; Sweetser MT; Forrestal F; Duda P
    J Neurol Sci; 2014 Jun; 341(1-2):22-7. PubMed ID: 24731783
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Natalizumab vs interferon beta 1a in relapsing-remitting multiple sclerosis: a head-to-head retrospective study.
    Lanzillo R; Quarantelli M; Bonavita S; Ventrella G; Lus G; Vacca G; Prinster A; Orefice G; Tedeschi G; Brescia Morra V
    Acta Neurol Scand; 2012 Nov; 126(5):306-14. PubMed ID: 22107083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study.
    Havrdova E; Galetta S; Hutchinson M; Stefoski D; Bates D; Polman CH; O'Connor PW; Giovannoni G; Phillips JT; Lublin FD; Pace A; Kim R; Hyde R
    Lancet Neurol; 2009 Mar; 8(3):254-60. PubMed ID: 19201654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD49d expression as a promising biomarker to monitor natalizumab efficacy.
    Defer G; Mariotte D; Derache N; Toutirais O; Legros H; Cauquelin B; Le Mauff B
    J Neurol Sci; 2012 Mar; 314(1-2):138-42. PubMed ID: 22050952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of relapsing-remitting multiple sclerosis after 24 doses of natalizumab: evidence from an Italian spontaneous, prospective, and observational study (the TY-STOP Study).
    Clerico M; Schiavetti I; De Mercanti SF; Piazza F; Gned D; Brescia Morra V; Lanzillo R; Ghezzi A; Bianchi A; Salemi G; Realmuto S; Sola P; Vitetta F; Cavalla P; Paolicelli D; Trojano M; Sormani MP; Durelli L
    JAMA Neurol; 2014 Aug; 71(8):954-60. PubMed ID: 24977406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The improvement of cognitive functions is associated with a decrease of plasma Osteopontin levels in Natalizumab treated relapsing multiple sclerosis.
    Iaffaldano P; Ruggieri M; Viterbo RG; Mastrapasqua M; Trojano M
    Brain Behav Immun; 2014 Jan; 35():176-81. PubMed ID: 23994630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative effectiveness of early natalizumab treatment in JC virus-negative relapsing-remitting multiple sclerosis.
    Campbell JD; McQueen RB; Miravalle A; Corboy JR; Vollmer TL; Nair K
    Am J Manag Care; 2013 Apr; 19(4):278-85. PubMed ID: 23725360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Occurrence of antibodies against natalizumab in relapsing multiple sclerosis patients treated with natalizumab.
    Sørensen PS; Jensen PE; Haghikia A; Lundkvist M; Vedeler C; Sellebjerg F; Koch-Henriksen N; Fogdell-Hahn A; Myhr KM; Hillert J; Gold R
    Mult Scler; 2011 Sep; 17(9):1074-8. PubMed ID: 21511692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sustained efficacy of natalizumab in the treatment of relapsing-remitting multiple sclerosis independent of disease activity and disability at baseline: real-life data from a Swiss cohort.
    Kallweit U; Jelcic I; Braun N; Fischer H; Zörner B; Schreiner B; Sokolov AA; Martin R; Weller M; Linnebank M
    Clin Neuropharmacol; 2012; 35(2):77-80. PubMed ID: 22318192
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of the effectiveness and safety of natalizumab for treating relapsing-remitting multiple sclerosis.
    Fernández-Megía MJ; Casanova B; Magraner MJ; Font-Noguera I; Poveda-Andrés JL
    Farm Hosp; 2011; 35(2):75-9. PubMed ID: 20685144
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Natalizumab as induction therapy in multiple sclerosis].
    Corlobé A; Charif M; Mania A; Outteryck O; de Sèze J; Labauge P
    Rev Neurol (Paris); 2014 Jan; 170(1):2-5. PubMed ID: 24125463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.